Maitake for Integrative Cancer Care

Study acronym: Maitake
StatusCompleted
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 5 more changesShow less
    • Final enrollment: 20 participants (planned 40)
    • Primary and study completion dates changed from estimate of May 15, 2026 to Apr 16, 2026
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints: details revised at 8 of 9 entries
    • Site details revised at 2 of 2 sites
  2. Primary completion date: Nov 15, 2025 to May 15, 2026
    • Study completion date: Dec 15, 2025 to May 15, 2026
    v4
  3. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Primary completion date: Nov 1, 2025 to Nov 15, 2025
    • Study completion date: Dec 1, 2025 to Dec 15, 2025
    • Start date changed from estimate of Oct 1, 2024 to Oct 15, 2024
    • Site details revised at 2 of 2 sites
  4. Start date: Jul 1, 2024 to Oct 1, 2024
    • Primary completion date: Aug 1, 2025 to Nov 1, 2025
    • Study completion date: Sep 1, 2025 to Dec 1, 2025
    v2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Maitake is an edible mushroom that is used for both its nutritional and medicinal properties. Human and animal studies have shown Maitake may help improve immune function; however, its effectiveness in people with cancer is not clear. The investigators aim to measure if Maitake has any immunomodulatory effects when given alongside conventional systemic cancer therapy.
Trial Details
NCT Number NCT06323473
Lead Sponsor The Canadian College of Naturopathic Medicine
Conditions
(from sponsor)		 Cancer
Related terms Neoplasms
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov